Personalising Your Approach to Heart Failure Treatment

Published: 10 January 2023

  • Views:

    Views Icon 3348
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

This video series is dedicated to the adoption of patient-reported outcomes (PROs) and initiation of guideline-directed medical therapy (GDMT) in daily practice. 

 

In this second discussion of the series, Prof Giuseppe Rosano (St George’s University Medical School, London, UK) and Dr Biykem Bozkurt (Baylor College of Medicine, Texas, US) consider how we can be personalising our approach to the use of SGLT-2 inhibitors as disease modifying heart failure (HF) treatments.

 

They begin by discussing how one should be initiating SGLT-2 inhibitors across the continuum of ejection fraction and across patients who are treatment naïve versus those already on existing HF medications. Referring to the recent clinical practice guidelines, Dr Bozkurt advocates the early initiation of SGLT-2 inhibitors and goes on to provide practical advice on the monitoring and continual use of these agents for better long-term outcomes.

 

Catch up now on the first video in this series 'Optimising Clinical Success With Foundational Heart Failure Treatment'.

 

 

This programme is supported by an unrestricted educational grant from AstraZeneca.

Key Learning Objectives

  • Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
  • Adopt shared decision-making with HF patients

Target Audience

  • Cardiologists
  • Heart Failure Specialists
  • Primary Care Physicians
  • Nurses
  • Pharmacists
  • Other allied HCPs

More from this programme

Part 1

Initiating SGLT-2 Inhibitors

In this opening video, Prof Rosano and Dr Bozkurt examine recent guidelines and consider best practice for initiating SGLT-2 inhibitors across the continuum of HF and in patients already on HF medication versus those who are treatment-naïve.

Part 2

Evolving the Management Approach - AEs and MDTs

Prof Rosano and Dr Bozkurt discuss the practicalities of continual management of HF patients on an SGLT-2 inhibitor, what to expect regarding adverse events and how the broader multidisciplinary team – including primary care, endocrinologists, nephrologists and even emergency medicine specialists – should be aware of the benefits of early SGLT-2 initiation in HF.

Faculty Biographies

Biykem  Bozkurt

Biykem Bozkurt

Dr Biykem Bozkurt is the Immediate Past President of the Heart Failure Society of America. 

Dr Bozkurt is a Professor of Medicine, an advanced heart failure and cardiac transplantation specialist, Medical Care Line Executive (Medicine Department Chair) at the DeBakey VA Medical Center; W.A. “Tex” and Deborah Moncrief, Jr., Chair; Mary and Gordon Cain Chair; Vice-Chair of Department of Medicine; Director of the Winters Center for Heart Failure and Associate Director of Cardiovascular Research Institute at Baylor College of Medicine. 

View full profile
Giuseppe Rosano

Giuseppe Rosano

Consultant Cardiologist and Professor of Cardiology (Hon)

Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London, UK where he is also the director of MSc Heart Failure.

His research interests focus on experimental and clinical pharmacology, heart failure, cardiac metabolism, diabetes and gender differences in cardiovascular diseases. Prof Rosano has been core member of the Cardiovascular Working Party of the European Medicines Agency and member of the Pricing and Reimbursement Committee of the Italian Drug Agency. He is the President-Elect of the Heart Failure Association Board (HFA), and Chairman of the Education Committee of the HFA. Prof Rosano is on the editorial board for European Journal of Heart Failure, European Heart Journal CV Pharmacotherapy, Cardiac Failure Reviews and Cardiovascular Diabetology. He has authored more than 500 peer…

View full profile